There are about 21071 clinical studies being (or have been) conducted in Spain. The country of the clinical trial is determined by the location of where the clinical research is being studied. Most studies are often held in multiple locations & countries.
Healthy and at risk (hypercholesterolemic) subjects consumed during 4 weeks 45 g/d of either olive pomace oil (OPO) or high oleic acid sunflower oil (HOSO) as the only dietary fat in a randomized, crossover trial. The effects on blood lipids, glucose homeostasis, endothelial function, inflammatory cytokines, oxidative stress biomarkers and anthropometry were measured.
The syndrome characterized by the persistence of symptoms typical of COVID-19, beyond 4 weeks after discharge, is called long COVID. Long COVID affects a high percentage of patients who have suffered from COVID-19, regardless of its severity. The various symptoms present in that patients affect the functionality and physical, mental and psychological capacities of patients. Therefore, it is necessary to implement therapeutic programs, based on exercises and techniques of physiotherapy, to help affected people to resume their work, family, social and sports activities; prior to illness. Given the context in which these programs must be developed, telecare is positioned as the most recommended care method to carry out the rehabilitation of these patients. The general objective of this study is to evaluate the effectiveness of a cardiorespiratory tele-rehabilitation program in persistent COVID-19 patients. Study participants (n=60) will be randomly assigned to one of two intervention groups. Group 1 will combine breathing exercises with aerobic exercise: walk; and group 2 will perform functional exercises in addition to respiratory physiotherapy with. All participants will be evaluated at the beginning of the intervention, at the end of it.
The SPRIMACC study is a prospective multicenter observational study with the primary endpoint to prospectively validate the Chole-Risk score in predicting a complicated postoperative course (post-operative major complications (Clavien-Dindo>=3a), length of stay (LOS) > 10 days or need of readmission within 30 days from the discharge) in patients undergoing Early Cholecystectomy (EC) for Acute Calculous Cholecystitis (ACC). The secondary endpoints of the study are to prospectively validate and compare other wellknown risk prediction models (the POSSUM/P-POSSUM score, the Modified Frailty Index (mFI), the Charlson Comorbidity Index (CCI), the American Society of Anesthesiologists (ASA) score and the APACHE II score) in predicting a complicated post-operative course in patients undergoing EC.
By-products from the wine industry pose serious problems of management, both from an economic and environmental point of view. Although traditionally the use of by-products of the wine sector has been limited to the production of biogas and energy, or its use as animal feed or agricultural fertilizer, there is greater interest in the use of these by-products as a potential source of functional ingredients. Cardiovascular diseases (CVD) are the main cause of mortality in Europe, with hypertension being one of the main CVD risk factors. It has been shown that lowering blood pressure through behavioral and pharmacological interventions significantly improves CVD. Currently, one of the most widely used pharmacological therapies to treat hypertension is based on the use of angiotensin converting enzyme (ACE) inhibitors such as Captopril or Enalapril. ACE plays a key role in arterial pressure regulation, catalyzing the production of angiotensin II, an octapeptide with potent vasoconstrictor activity. In addition, ACE catalyzes the inactivation of bradykinin, peptide with vasodilator activity. The evaluation of various potential by-products of the wine industry for the generation of functional ingredients showed that an extract from the wine industry presented beneficial effects on blood pressure in in vitro models as well as in vivo models using rats with hypertension.
The widespread availability of efficient contraception as well as women's increased education has led to childbearing postponement. Combined with the increased recognition of the concept of "ovarian aging", this has opened the Pandora´s box of EOC, which is currently considered a safe and cost-efficient approach among assisted reproduction techniques. Previous studies have shown that two main factors determine the CLBR after EOC: 1) patient's age at the time of oocyte banking, and 2) the number of oocytes retrieved. Therefore, measures aiming at increasing the oocyte yield, specially the number of mature oocytes retrieved, will maximize the success of this technique. In the last few years, the dual trigger for final oocyte maturation has emerged has an approach that seems to improve both oocyte yield and quality when compared to the hCG trigger alone. Nowadays, the standard of care in EOC patients is final oocyte maturation with a single bolus of GnRH-a. Understanding the impact of the dual trigger on the number of MII oocytes retrieved in patients undergoing EOC will improve the treatment protocols and allow for a better patient counselling.
CarpeDiem is a mobile application which provides personalized and holistic recommendations in the area of diet, physical activity and sleep to help their users adopt a healthier lifestyle. In this study it is hypothesized that the usage of this application can achieve a more effective lifestyle improvement than an intervention with the use of wearables, their respective generic applications and general healthy lifestyle recommendations. Therefore, this study aims to assess whether the incorporation of a mobile application such as CarpeDiem, which includes smart, personalized and holistic recommendations related to a healthy lifestyle (diet, physical activity and sleep) is associated with a more pronounced change in healthy lifestyle habits than a passive monitoring approach using wearables and the administration of general recommendations. This clinical trial consists of a multicenter pilot study performed at the headquarters of the Technology Center of Catalonia (Eurecat), randomized, parallel and controlled, performed with healthy adults (18 to 65 years old). 100 subjects will be recruited, 50 as an intervention group and 50 as a control group. The study is scheduled to begin in June 2021. Both groups will receive an activity tracker (Fitbit Inspire HR 2). The intervention group will also receive instructions to download and use the CarpeDiem application. Through the CarpeDiem application, participants will be able to answer follow-up questionnaires, perform missions related to the healthy consumption of various food groups, monitor their physical activity and sleep, and receive periodic, personalized and holistic recommendations based on the three pillars of health. The control group will receive instructions to download the Fitbit application and will additionally receive general recommendations for healthy lifestyle habits through standardized documents. Both groups will be provided access to the initial and final questionnaires that will be done online. All participants must return the signed informed consent either with a digital signature or by mail to the Eurecat-Barcelona headquarters. The main variable of the study is: the Mediterranean lifestyle index, calculated from the short MEDLIFE questionnaire with 28 items, validated for the Spanish adult population. The secondary variables are: Diet related: Food intake and food groups taken from the Food Frequency Questionnaire (CFCA). Diet diversity index calculated from the CFCA. Related to physical activity: Total physical activity in MET-minutes / week, extracted from the IPAQ questionnaire. Data referring to daily activity (minutes sitting and moderate and intense physical activity and number of steps taken) measured with the activity bracelet. Sleep-related: Sleep quality index, derived from the Pittsburg Sleep Quality Questionnaire (PSQI). Data referring to users' daily sleep (sleep duration, efficiency, start and end) measured with the activity bracelet. Related to the user's experience in using the application, evaluated through the UEQ questionnaire. Only at the end of the intervention. In total, subjects will receive 3 visits: Visit 0, pre-screening visit before randomization to check inclusion / exclusion criteria, using an online form. Visit 1, after randomization, inclusion visit. Participants will receive the activity bracelet and informed consent at their homes. During this visit, participants will answer the questionnaires using online forms. Visit 2, after three months, final visit of the study intervention. Participants will answer the questionnaires using online forms.
The purpose of this study is to evaluate the efficacy and safety of nipocalimab versus placebo in participants with moderate to severe active rheumatoid arthritis (RA).
The purpose of this study is to determine the recommended phase 2 dose (RP2D) regimen(s) of JNJ-78306358 in Part 1 (Dose Escalation) and to determine the safety of JNJ-78306358 at the RP2D regimen(s) in Part 2 (Dose Expansion).
To analyze the short-term effect of kinesiology taping on sitting postural control in moderate and severe cerebral palsy
This study will consider the safety and effectiveness of a study drug, CAN04, in combination with FOLFIRINOX, in the treatment of metastatic pancreatic ductal adenocarcinoma.